Diagnostic utility of immunohistochemical panel in various thyroid pathologies

Langenbeck's Archives of Surgery

Volumn 395, Issue 7, 2010, Pages 885-891

  Ozolins, Arturs ^a,b   Narbuts, Zenons ^a,b   Strumfa, Ilze ^b   Volanska, Guna ^b   Gardovskis, Janis ^a,b  

^a PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

CD56; E cadherin; HBME 1; Immunohistochemistry; Thyroid nodules

Indexed keywords

CD56 ANTIGEN; CYCLOOXYGENASE 2; KI 67 ANTIGEN; PROTEIN HBME 1; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; BENIGN TUMOR; CELL PROLIFERATION; COLLOID GOITER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; GOITER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RATING SCALE; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID FOLLICULAR ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID TUMOR;

ANTIGENS, CD56; BIOPSY, FINE-NEEDLE; CADHERINS; CYCLOOXYGENASE 2; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 78149410346     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00423-010-0690-6     Document Type: Article

References (56)

1. H Gharib E Papini 2007 Thyroid nodules: clinical importance, assessment, and treatment Endocrinol Metab Clin N Am 36 707 735 1:CAS:528:DC%2BD2sXhtFCgsrjM 10.1016/j.ecl.2007.04.009 (Pubitemid 47135591)
2. D Topliss 2004 Thyroid incidentaloma: the ignorant in pursuit of the impalpable Clin Endocrinol (Oxf) 60 18 20 10.1111/j.1365-2265.2004.01956.x (Pubitemid 38183492)
3. SA Hundahl, et al. 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 Cancer 83 2638 2648 1:STN:280:DyaK1M%2FovFylug%3D%3D 10.1002/(SICI)1097-0142(19981215)83:12<2638: :AID-CNCR31>3.0.CO;2-1 9874472 (Pubitemid 29019586)
4. DJ Finley, et al. 2004 Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules J Clin Endocrinol Metab 89 3214 3223 1:CAS:528:DC%2BD2cXlslegs70%3D 10.1210/jc.2003-031811 15240595 (Pubitemid 38951886)
5. YY Liu, et al. 2008 Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma Eur J Endocrinol 158 375 384 1:CAS:528:DC%2BD1cXjsFylurw%3D 10.1530/EJE-07-0492 18299472 (Pubitemid 351405003)
6. BR Haugen WW Woodmansee MT McDermott 2002 Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours Clin Endocrinol (Oxf) 56 281 290 1:CAS:528:DC%2BD38XjtlKhtLw%3D 10.1046/j.1365-2265. 2002.01500.x (Pubitemid 34310003)
7. Bancroft JD, Gamble M (2003) Theory and practice of histological techniques, international edition. Churchill Livingstone, Edinburgh
8. RA DeLellis 2006 Pathology and genetics of thyroid carcinoma J Surg Oncol 94 662 669 1:CAS:528:DC%2BD2sXislOlsg%3D%3D 10.1002/jso.20700 17131411 (Pubitemid 44902064)
9. Altman DG, Machin D, Bryant TN, Gardner MJ (2005) Statistics with confidence, 2nd edn. BMJ, Bristol
10. K Sheibani, et al. 1992 Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma Hum Pathol 23 107 116 1:STN:280:DyaK387lsFKlsw%3D%3D 10.1016/0046-8177(92)90231-Q 1740296
11. HA Saleh, et al. 2010 Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules Diagn Pathol 5 9 10.1186/1746-1596-5-9 20181018
12. M Miettinen P Karkkainen 1996 Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity malignant tumours Virchows Arch 429 213 219 1:CAS:528:DyaK2sXlslCg 10.1007/BF00198336 8972756
13. MJ Sack, et al. 1997 HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma Mod Pathol 10 668 674 1:STN:280:DyaK2szotVertQ%3D%3D 9237176
14. KT Mai, et al. 2002 Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hurthle cell and/or apocrine-like changes Histopathology 40 133 142 1:STN:280:DC%2BD383itFSgtA%3D%3D 10.1046/j.1365-2559.2002.01315.x 11952857 (Pubitemid 34122115)
15. Y Ito, et al. 2005 HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma Anticancer Res 25 179 182 1:CAS:528:DC%2BD2MXjsFSgu7o%3D 15816536
16. M Papotti, et al. 2005 Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential Mod Pathol 18 541 546 1:CAS:528:DC%2BD2MXisVShtL8%3D 10.1038/modpathol.3800321 15529186 (Pubitemid 40478118)
17. ML Prasad, et al. 2005 Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors Mod Pathol 18 48 57 1:CAS:528:DC%2BD2MXisl2n 10.1038/modpathol. 3800235 15272279 (Pubitemid 40128094)
18. ED Rossi, et al. 2006 Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid Histopathology 48 795 800 1:STN:280: DC%2BD283ptleqsA%3D%3D 10.1111/j.1365-2559.2006.02428.x 16722927 (Pubitemid 43800938)
19. E Saggiorato, et al. 2005 Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application Endocr Relat Cancer 12 305 317 1:STN:280:DC%2BD2M3pvF2qtA%3D%3D 10.1677/erc.1.00944 15947105 (Pubitemid 40896449)
20. de Micco, et al. 2008 Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV Br J Cancer 98 818 823 10.1038/sj.bjc.6604194 18212751 (Pubitemid 351272603)
21. MR Nasr, et al. 2006 Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining Mod Pathol 19 1631 1637 1:CAS:528:DC%2BD28Xht1akurzP 10.1038/modpathol.3800705 16998461 (Pubitemid 44789932)
22. HA Saleh, et al. 2009 Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy Cytojournal 6 18 10.4103/1742-6413.55894 19826479
23. ME Nga, et al. 2008 HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma Diagn Cytopathol 36 550 556 10.1002/dc.20841 18618720
24. T Scognamiglio, et al. 2006 Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma Am J Clin Pathol 126 700 708 1:CAS:528:DC%2BD28XhtlSktrnE 10.1309/044V86JN2W3CN5YB 17050067
25. T Mase, et al. 2003 HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm Endocr J 50 173 177 10.1507/endocrj.50.173 12803237 (Pubitemid 36554108)
26. YJ Park, et al. 2007 Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules J Korean Med Sci 22 621 628 10.3346/jkms.2007.22.4.621 17728499
27. J Zeromski, et al. 1992 Expression of CD56 (NKH-1) differentiation antigen in human thyroid epithelium Clin Exp Immunol 89 474 478 1:CAS:528:DyaK3sXitVGltg%3D%3D 10.1111/j.1365-2249.1992.tb06983.x 1381304
28. D El Demellawy A Nasr S Alowami 2009 An updated review on the clinicopathologic aspects of arrhythmogenic right ventricular cardiomyopathy Am J Forensic Med Pathol 30 78 83 10.1097/PAF.0b013e318187379e 19237863
29. D El Demellawy A Nasr S Alowami 2008 Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid Diagn Pathol 3 5 10.1186/1746-1596-3-5 18254952
30. S Scarpino, et al. 2007 Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells J Pathol 212 411 419 1:CAS:528:DC%2BD2sXhtVWiurnL 10.1002/path.2183 17573672 (Pubitemid 47099018)
31. S Hirohashi Y Kanai 2003 Cell adhesion system and human cancer morphogenesis Cancer Sci 94 575 581 1:CAS:528:DC%2BD2cXhs1Kgs7Y%3D 10.1111/j.1349-7006.2003.tb01485.x 12841864 (Pubitemid 36975010)
32. S Eidelman, et al. 1989 Expression of the cell-cell adhesion glycoprotein cell-CAM 120/80 in normal human tissues and tumors Am J Pathol 135 101 110 1:CAS:528:DyaL1MXlslWrs70%3D 2774055
33. G Brabant, et al. 1993 E-cadherin: a differentiation marker in thyroid malignancies Cancer Res 53 4987 4993 1:CAS:528:DyaK2cXlvFCk 8402689
34. P Soares, et al. 1997 E-cadherin gene alterations are rare events in thyroid tumors Int J Cancer 70 32 38 1:STN:280:DyaK2s7jvVSlsw%3D%3D 10.1002/(SICI)1097-0215(19970106)70:1<32::AID-IJC5>3.0.CO;2-7 8985087 (Pubitemid 27059702)
35. R von Wasielewski, et al. 1997 Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome Cancer Res 57 2501 2507
36. JR Graff, et al. 1998 Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma Cancer Res 58 2063 2066 1:CAS:528:DyaK1cXjt12hsb8%3D 9605742
37. YL Choi, et al. 2005 Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas J Korean Med Sci 20 853 859 1:CAS:528:DC%2BD2MXht1CrurnK 10.3346/jkms.2005.20.5.853 16224162
38. P Smyth, et al. 2001 Real-time quantitative analysis of E-cadherin expression in ret/PTC-1-activated thyroid neoplasms Int J Surg Pathol 9 265 272 1:CAS:528:DC%2BD38XnvVSgsg%3D%3D 10.1177/106689690100900402 12574841
39. E Fosslien 2000 Molecular pathology of cyclooxygenase-2 in neoplasia Ann Clin Lab Sci 30 3 21 1:CAS:528:DC%2BD3cXht1altr8%3D 10678579
40. Y Ito, et al. 2003 Cyclooxygenase-2 expression in thyroid neoplasms Histopathology 42 492 497 1:STN:280:DC%2BD3s7psVymtg%3D%3D 10.1046/j.1365-2559. 2003.01624.x 12713627 (Pubitemid 36605593)
41. MC Specht, et al. 2002 Cyclooxygenase-2 expression in thyroid nodules J Clin Endocrinol Metab 87 358 363 1:CAS:528:DC%2BD38XntVykug%3D%3D 10.1210/jc.87.1.358 11788675 (Pubitemid 34084715)
42. MB Casey, et al. 2004 Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions Endocr Pathol 15 107 116 1:CAS:528:DC%2BD2cXnvFWgsbc%3D 10.1385/EP:15:2:107 15299197 (Pubitemid 39179423)
43. AJ Cornetta, et al. 2002 Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis Laryngoscope 112 238 242 1:CAS:528:DC%2BD38XnvVegsLs%3D 10.1097/00005537-200202000-00008 11889377
44. SJ Kim, et al. 2003 Immunohistochemical expression of COX-2 in thyroid nodules Korean J Intern Med 18 225 229 1:CAS:528:DC%2BD3sXktVKgtr4%3D 14717230
45. F Nose, et al. 2002 Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase Am J Clin Pathol 117 546 551 1:CAS:528:DC%2BD38XjtVCns7Y%3D 10.1309/9CCJ-XQ8P-PMFM-M65K 11939728 (Pubitemid 34823683)
46. DM Haynik RA Prayson 2005 Immunohistochemical expression of cyclooxygenase 2 in follicular carcinomas of the thyroid Arch Pathol Lab Med 129 736 741 1:CAS:528:DC%2BD2MXlsFeiuro%3D 15913419
47. AG Saad, et al. 2006 Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure J Clin Endocrinol Metab 91 2672 2677 1:CAS:528: DC%2BD28XntFWgtLg%3D 10.1210/jc.2006-0417 16670159 (Pubitemid 44024635)
48. A Ziad el, et al. 2008 Immunoexpression of TTF-1 and Ki-67 in a coexistent anaplastic and follicular thyroid cancer with rare long-life surviving Folia Histochem Cytobiol 46 461 464 10.2478/v10042-008-0071-y 19141399
49. I Novosel, et al. 2006 p53, bcl-2 and Ki-67 in the diagnosis of insular thyroid gland cancer. Case report with a review of literature Lijec Vjesn 128 264 267 17128663
50. LA Akslen JE Varhaug 1995 Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival Cancer 76 1643 1654 1:STN:280:DyaK283itlahtA%3D%3D 10.1002/1097-0142(19951101)76:9<1643:: AID-CNCR2820760922>3.0.CO;2-# 8635070
51. J Martinez I Georgoff AJ Levine 1991 Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein Genes Dev 5 151 159 1:CAS:528:DyaK3MXhs1Wkt7k%3D 10.1101/gad.5.2.151 1995413
52. CA Finlay PW Hinds AJ Levine 1989 The p53 proto-oncogene can act as a suppressor of transformation Cell 57 1083 1093 1:CAS:528:DyaL1MXkslagtb8%3D 10.1016/0092-8674(89)90045-7 2525423 (Pubitemid 19169804)
53. N Morita Y Ikeda H Takami 2008 Clinical significance of p53 protein expression in papillary thyroid carcinoma World J Surg 32 2617 2622 10.1007/s00268-008-9756-9 18836853
54. Y Dobashi, et al. 1993 Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma Am J Surg Pathol 17 375 381 1:STN:280:DyaK3s3mtlartg%3D%3D 10.1097/00000478-199304000-00008 7684202
55. BK Chen, et al. 1999 Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage Int J Oncol 15 893 898 1:CAS:528:DyaK1MXnsFGis7k%3D 10536170
56. T Kobayashi, et al. 1995 Clinicopathological findings and p53 expression of thyroid cancer in children Surg Today 25 217 221 1:CAS:528:DyaK2MXmslSktb4%3D 10.1007/BF00311530 7640449